166 related articles for article (PubMed ID: 35182276)
21. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Loi S; Haibe-Kains B; Desmedt C; Wirapati P; Lallemand F; Tutt AM; Gillet C; Ellis P; Ryder K; Reid JF; Daidone MG; Pierotti MA; Berns EM; Jansen MP; Foekens JA; Delorenzi M; Bontempi G; Piccart MJ; Sotiriou C
BMC Genomics; 2008 May; 9():239. PubMed ID: 18498629
[TBL] [Abstract][Full Text] [Related]
22. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Wolmark N; Mamounas EP; Baehner FL; Butler SM; Tang G; Jamshidian F; Sing AP; Shak S; Paik S
J Clin Oncol; 2016 Jul; 34(20):2350-8. PubMed ID: 27217450
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract][Full Text] [Related]
27. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
29. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
30. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer.
Li Y; Li Y; Wedrén S; Li G; Charn TH; Desai KV; Bonnard C; Czene K; Humphreys K; Darabi H; Einarsdóttir K; Heikkinen T; Aittomäki K; Blomqvist C; Chia KS; Nevanlinna H; Hall P; Liu ET; Liu J
Breast Cancer Res; 2011 Jan; 13(1):R10. PubMed ID: 21269472
[TBL] [Abstract][Full Text] [Related]
31. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
32. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Onitilo AA; McCarty CA; Wilke RA; Glurich I; Engel JM; Flockhart DA; Nguyen A; Li L; Mi D; Skaar TC; Jin Y
Breast Cancer Res Treat; 2009 Jun; 115(3):643-50. PubMed ID: 19082882
[TBL] [Abstract][Full Text] [Related]
34. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
Abdel-Fatah TMA; Broom RJ; Lu J; Moseley PM; Huang B; Li L; Liu S; Chen L; Ma RZ; Cao W; Wang X; Li Y; Perry JK; Aleskandarany M; Nolan CC; Rakha EA; Lobie PE; Chan SYT; Ellis IO; Hwang LA; Lane DP; Green AR; Liu DX
Br J Cancer; 2019 Apr; 120(7):728-745. PubMed ID: 30816325
[TBL] [Abstract][Full Text] [Related]
35. Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer.
Jeon S; Choi JY; Lee KM; Park SK; Yoo KY; Noh DY; Ahn SH; Kang D
Breast Cancer Res Treat; 2010 Jun; 121(3):737-42. PubMed ID: 19941161
[TBL] [Abstract][Full Text] [Related]
36. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
[TBL] [Abstract][Full Text] [Related]
37. Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Liu J; Li J; Wang H; Wang Y; He Q; Xia X; Hu ZY; Ouyang Q
J Transl Med; 2019 Jan; 17(1):27. PubMed ID: 30646914
[TBL] [Abstract][Full Text] [Related]
38. Soy Foods Might Weaken the Sensitivity of Tamoxifen in Premenopausal Patients With Lumina A Subtype of Breast Cancer.
Deng K; Mo S; Liu X; Chen J; Zhang Q; Chen X; Chen J; Dai S
Clin Breast Cancer; 2019 Apr; 19(2):e337-e342. PubMed ID: 30733051
[TBL] [Abstract][Full Text] [Related]
39. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
40. Estrogen Receptor 1 Gene (ESR1) rs2234693 Polymorphism and Breast Cancer Risk in Saudi Women.
Al-Amri RJ; Alotibi MKH; Al-Raddadi RI; Shebli WTY; Fallatah EIY; Alhujaily AS; Mohamed HS
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3235-3240. PubMed ID: 33247680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
